{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:05:44Z","timestamp":1792292744105,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Abnormalities in biochemical parameters and changes in eating habits are considered complications of obesity. Oleoylethanolamide (OEA), an endocannabinoid-like compound, has been shown to have protective effects on many metabolic disorders. Given this evidence, the present study aimed to assess the effects of OEA on lipid profile parameters, fasting blood sugar (FBS), and dietary habits in healthy obese people.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this randomized, double-blind, placebo-controlled clinical trial, which was carried out in 2016 in Tabriz, Iran, 60 obese people were enrolled in the study based on inclusion criteria. The intervention group consumed 125\u00a0mg of OEA capsules, and the placebo group received the same amount of starch twice for 8 weeks. Blood samples (5 mL) were taken at baseline and the end of the study in a fasting state. Serum concentrations of FBS, triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC) were measured by enzymatic methods using commercial kits. The low-density lipoprotein cholesterol (LDL-C) concentration was obtained using the Friede-Wald formula. To assess dietary habits, a food frequency questionnaire (147 items) was used at baseline and the end of the study. A value less than &lt;\u20090.05 was considered to indicate statistical significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The TG concentration decreased significantly in the intervention group (mean (SD): 166.29 (70.01) mg\/dL to 142.22 (48.05) mg\/dL, <jats:italic>p<\/jats:italic>\u2009=\u20090.047). Changes in the placebo group were not significant (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). After adjusting for baseline values and demographic characteristics, the difference in TG between groups remained significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.044). Changes in other biochemical parameters were not significant. There was no significant difference between or within groups in terms of food groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>OEA, as a complementary agent, plays a protective role in TG regulation. However, future studies with longer durations are needed to explore the impact of OEA on regulating dietary habits and to identify the mechanisms related to metabolic abnormalities in obese people.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>The study was registered in the Iranian Registry of Clinical Trials (IRCT) center as IRCT201607132017N30 with URL. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.IRCT.IR\">www.IRCT.IR<\/jats:ext-link> in date 03\/10\/2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-024-01738-7","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:03:13Z","timestamp":1728370993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Alireza","family":"Ostadrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Khajebishak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Payahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"1738_CR1","doi-asserted-by":"crossref","unstructured":"Nattagh-Eshtivani E, Gheflati A, Barghchi H, Rahbarinejad P, Hachem K, Shalaby MN, et al. The role of pycnogenol in the control of inflammation and oxidative stress in chronic diseases: molecular aspects. Phytother Res. 2022;36(6):2352\u201374.","DOI":"10.1002\/ptr.7454"},{"key":"1738_CR2","doi-asserted-by":"crossref","unstructured":"Taheri S, Rashidmayvan M, Jamshidi S, Jazinaki MS, Pahlavani N. The effect of Royal jelly on liver enzymes and glycemic indices: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2023;77:102974.","DOI":"10.1016\/j.ctim.2023.102974"},{"key":"1738_CR3","doi-asserted-by":"crossref","unstructured":"Payahoo L, Ostadrahimi A, Farrin N, Khaje-Bishak Y. Effects of n-3 Polyunsaturated Fatty Acid Supplementation on Serum Leptin Levels, Appetite Sensations, and Intake of Energy and Macronutrients in Obese People: A Randomized Clinical Trial. J Diet Suppl. 2018;15(5):596\u2013605.","DOI":"10.1080\/19390211.2017.1360975"},{"key":"1738_CR4","doi-asserted-by":"publisher","first-page":"f1515","DOI":"10.1136\/bmj.f1515","volume":"346","author":"M Franco","year":"2013","unstructured":"Franco M, Bilal U, Ordu\u00f1ez P, Benet M, Morej\u00f3n A, Caballero B, et al. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980\u20132010: repeated cross sectional surveys and ecological comparison of secular trends. Bmj. 2013;346:f1515.","journal-title":"Bmj"},{"key":"1738_CR5","unstructured":"Payahoo L, Ostadrahimi A, Mobasseri M, Bishak YK. Anethum graveolens L. supplementation has anti-inflammatory effect in type 2 diabetic patients.\u00a0Indian J Tradit Knowl. 2014;13(3):461\u20135."},{"issue":"5","key":"1738_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Reviews Endocrinol. 2019;15(5):288\u201398.","journal-title":"Nat Reviews Endocrinol"},{"key":"1738_CR7","doi-asserted-by":"crossref","unstructured":"Konnopka A. How relevant is the BMI for cost-of-illness studies in the 21st century? Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(7):719\u201321.","DOI":"10.1080\/14737167.2023.2230365"},{"issue":"1","key":"1738_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s41043-023-00419-w","volume":"42","author":"B Abiri","year":"2023","unstructured":"Abiri B, Ahmadi AR, Amini S, Akbari M, Hosseinpanah F, Madinehzad SA, et al. Prevalence of overweight and obesity among Iranian population: a systematic review and meta-analysis. J Health Popul Nutr. 2023;42(1):70.","journal-title":"J Health Popul Nutr"},{"issue":"8","key":"1738_CR9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/00325481.2016.1243005","volume":"128","author":"PA Kushner","year":"2016","unstructured":"Kushner PA, Cobble ME. Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med. 2016;128(8):848\u201358.","journal-title":"Postgrad Med"},{"key":"1738_CR10","doi-asserted-by":"publisher","first-page":"114624","DOI":"10.1016\/j.biopha.2023.114624","volume":"162","author":"H Barghchi","year":"2023","unstructured":"Barghchi H, Dehnavi Z, Nattagh-Eshtivani E, Alwaily ER, Almulla AF, Kareem AK, et al. The effects of Chlorella vulgaris on cardiovascular risk factors: a comprehensive review on putative molecular mechanisms. Biomed Pharmacother. 2023;162:114624.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1738_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/fsn3.2684","volume":"10","author":"E Nattagh-Eshtivani","year":"2022","unstructured":"Nattagh-Eshtivani E, Pahlavani N, Ranjbar G, Gholizadeh Navashenaq J, Salehi\u2010Sahlabadi A, Mahmudiono T, et al. Does propolis have any effect on rheumatoid arthritis? A review study. Food Sci Nutr. 2022;10(4):1003\u201320.","journal-title":"Food Sci Nutr"},{"key":"1738_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.metabol.2018.11.005","volume":"92","author":"J Vekic","year":"2019","unstructured":"Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71\u201381.","journal-title":"Metabolism"},{"issue":"4","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/nu5041218","volume":"5","author":"B Klop","year":"2013","unstructured":"Klop B, Elte JWF, Castro Cabezas M. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218\u201340.","journal-title":"Nutrients"},{"issue":"3","key":"1738_CR14","first-page":"824","volume":"2","author":"AK Singh","year":"2011","unstructured":"Singh AK, Singh S, Singh N, Agrawal N, Gopal K. Obesity and dyslipidemia. Int J Biol Med Res. 2011;2(3):824\u20138.","journal-title":"Int J Biol Med Res"},{"key":"1738_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.706978","volume":"12","author":"X Lin","year":"2021","unstructured":"Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12: 706978.","journal-title":"Front Endocrinol"},{"key":"1738_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00863","volume":"14","author":"MT Flores-Dorantes","year":"2020","unstructured":"Flores-Dorantes MT, D\u00edaz-L\u00f3pez YE, Guti\u00e9rrez-Aguilar R. Environment and gene association with obesity and their impact on neurodegenerative and neurodevelopmental diseases. Front NeuroSci. 2020;14: 863.","journal-title":"Front NeuroSci"},{"key":"1738_CR17","doi-asserted-by":"crossref","unstructured":"Beltr\u00e1n-Carrillo VJ, Meg\u00edas \u00c1, Gonz\u00e1lez-Cutre D, Jim\u00e9nez-Loaisa A. Elements behind sedentary lifestyles and unhealthy eating habits in individuals with severe obesity. Int J Qual Stud Health Well-being. 2022;17(1):1\u201311.","DOI":"10.1080\/17482631.2022.2056967"},{"issue":"2","key":"1738_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.pcad.2018.06.001","volume":"61","author":"RF Kushner","year":"2018","unstructured":"Kushner RF. Weight loss strategies for treatment of obesity: lifestyle management and pharmacotherapy. Prog Cardiovasc Dis. 2018;61(2):246\u201352.","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.15171\/apb.2018.056","volume":"8","author":"L Payahoo","year":"2018","unstructured":"Payahoo L, Khajebishak Y, Jafarabadi MA, Ostadrahimi A. Oleoylethanolamide supplementation reduces inflammation and oxidative stress in obese people: a clinical trial. Adv Pharm Bull. 2018;8(3):479\u201387.","journal-title":"Adv Pharm Bull"},{"key":"1738_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.appet.2018.05.129","volume":"128","author":"P Laleh","year":"2018","unstructured":"Laleh P, Yaser K, Abolfazl B, Shahriar A, Mohammad AJ, Nazila F, et al. Oleoylethanolamide increases the expression of PPAR-\u0391 and reduces appetite and body weight in obese people: a clinical trial. Appetite. 2018;128:44\u20139.","journal-title":"Appetite"},{"key":"1738_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.nbd.2013.10.008","volume":"62","author":"R Gonz\u00e1lez-Aparicio","year":"2014","unstructured":"Gonz\u00e1lez-Aparicio R, Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson s disease. Neurobiol Dis. 2014;62:416\u201325.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-7682-4-28","volume":"4","author":"K Lueneberg","year":"2011","unstructured":"Lueneberg K, Dom\u00ednguez G, Arias-Carri\u00f3n O, Palomero-Rivero M, Mill\u00e1n-Aldaco D, Mor\u00e1n J, et al. Cellular viability effects of fatty acid amide hydrolase inhibition on cerebellar neurons. Int Archives Med. 2011;4(1):1\u20137.","journal-title":"Int Archives Med"},{"issue":"1","key":"1738_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/mol.104.006353","volume":"67","author":"JL Verme","year":"2005","unstructured":"Verme JL, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-\u03b1 mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15\u20139.","journal-title":"Mol Pharmacol"},{"issue":"10","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/157018006778631901","volume":"3","author":"B Brito","year":"2006","unstructured":"Brito B, Castro R, Cabrera de Leon A. Oleoylethanolamide: a molecular cross-talk with leptin in feeding behaviour regulation. Lett Drug Des Discov. 2006;3(10):741\u20136.","journal-title":"Lett Drug Des Discov"},{"key":"1738_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00018-004-4494-0","volume":"62","author":"J Lo Verme","year":"2005","unstructured":"Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci. 2005;62:708\u201316.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/01.RES.0000262653.84850.8b","volume":"100","author":"LL Zhang","year":"2007","unstructured":"Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, et al. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circul Res. 2007;100(7):1063\u201370.","journal-title":"Circul Res"},{"issue":"4","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/FJC.0000000000000413","volume":"68","author":"X Xu","year":"2016","unstructured":"Xu X, Guo H, Jing Z, Yang L, Chen C, Peng L, et al. N-oleoylethanolamine reduces inflammatory cytokines and adhesion molecules in TNF-\u03b1-induced human umbilical vein endothelial cells by activating CB2 and PPAR-\u03b1. J Cardiovasc Pharmacol. 2016;68(4):280\u201391.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1738_CR28","doi-asserted-by":"crossref","unstructured":"Tutunchi H, Ostadrahimi A, Saghafi-Asl M, Hosseinzadeh-Attar M-J, Shakeri A, Asghari-Jafarabadi M, et al. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: effects on metabolic parameters, anthropometric indices, and expression of PPAR-\u03b1, UCP1, and UCP2 genes. Pharmacol Res. 2020;156:1\u201311.","DOI":"10.1016\/j.phrs.2020.104770"},{"issue":"3","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jphs.2014.12.001","volume":"127","author":"L Li","year":"2015","unstructured":"Li L, Li L, Chen L, Lin X, Xu Y, Ren J, et al. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats. J Pharmacol Sci. 2015;127(3):244\u201350.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/obr.12630","volume":"19","author":"J Sihag","year":"2018","unstructured":"Sihag J, Jones P. Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour. Obes Rev. 2018;19(2):178\u201397.","journal-title":"Obes Rev"},{"key":"1738_CR31","doi-asserted-by":"crossref","unstructured":"Dipasquale P, Romano A, Cianci S, Righetti L, Gaetani S. Oleoylethanolamide: a new player in energy metabolism control. Role in food intake. Drug Discovery Today. 2010;7(3\u20134):169\u201374.","DOI":"10.1016\/j.ddmec.2011.01.004"},{"key":"1738_CR32","doi-asserted-by":"publisher","first-page":"104301","DOI":"10.1016\/j.appet.2019.05.032","volume":"141","author":"L Payahoo","year":"2019","unstructured":"Payahoo L, Khajebishak Y, Alivand MR, Soleimanzade H, Alipour S, Barzegari A, et al. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: a randomized clinical trial. Appetite. 2019;141:104301.","journal-title":"Appetite"},{"key":"1738_CR33","doi-asserted-by":"crossref","unstructured":"Najafi M, Nazari Z, Shamsi R, Nikpayam O, Bahrami A, Hekmatdoost A et al. Dietary patterns and risk of cervical cancer: a case-control study. Eur J Gynaecol Oncol. 2020;41(6):943\u20138.","DOI":"10.31083\/j.ejgo.2020.06.2149"},{"issue":"3","key":"1738_CR34","first-page":"33","volume":"9","author":"M Ghanavati","year":"2014","unstructured":"Ghanavati M, Rashidkhani B, Behrooz M, Sarli R, Moradi B. The relationship between the intake of some macronutrients and Dietry Antioxidants and Risk of Age-related cataract in adults: a Case Control. Iran J Nutr Sci Food Technol. 2014;9(3):33\u201344.","journal-title":"Iran J Nutr Sci Food Technol"},{"issue":"1","key":"1738_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-511X-11-127","volume":"11","author":"GT Mangine","year":"2012","unstructured":"Mangine GT, Gonzalez AM, Wells AJ, McCormack WP, Fragala MS, Stout JR, et al. The effect of a dietary supplement (N-oleyl-phosphatidyl-ethanolamine and epigallocatechin gallate) on dietary compliance and body fat loss in adults who are overweight: a double-blind, randomized control trial. Lipids Health Dis. 2012;11(1):1\u20138.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"1738_CR36","first-page":"167","volume":"9","author":"AM Kawalec","year":"2019","unstructured":"Kawalec AM, Kawalec AM. Analysis of the body composition of young adults and the frequency of occurrence of so-called normal weight obesity: a pilot study. Piel\u0119gniarstwo i Zdrowie Publiczne Nurs Public Health. 2019;9(3):167\u201371.","journal-title":"Piel\u0119gniarstwo i Zdrowie Publiczne Nurs Public Health"},{"key":"1738_CR37","doi-asserted-by":"crossref","unstructured":"Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:1\u201313.","DOI":"10.1016\/j.biopha.2021.111315"},{"key":"1738_CR38","unstructured":"Verma A, Verma D, Bansal P, Bansal A. Oleoylethanolamide-based treatment in obesity: a retrospective analysis of 100 cases from a single center in the northern territory of India.\u00a0Int J Sci Res. 2019;8(7):502\u20137."},{"issue":"8","key":"1738_CR39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.neuropharm.2005.02.013","volume":"48","author":"J Fu","year":"2005","unstructured":"Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-\u03b1 agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005;48(8):1147\u201353.","journal-title":"Neuropharmacology"},{"issue":"40","key":"1738_CR40","doi-asserted-by":"publisher","first-page":"42530","DOI":"10.18632\/oncotarget.6466","volume":"6","author":"L Chen","year":"2015","unstructured":"Chen L, Li L, Chen J, Li L, Zheng Z, Ren J, et al. Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget. 2015;6(40):42530.","journal-title":"Oncotarget"},{"issue":"8","key":"1738_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082589","volume":"13","author":"R Tovar","year":"2021","unstructured":"Tovar R, Gavito AL, Vargas A, Soverchia L, Hernandez-Folgado L, Jagerovic N, et al. Palmitoleoylethanolamide is an efficient anti-obesity endogenous compound: comparison with oleylethanolamide in diet-induced obesity. Nutrients. 2021;13(8): 2589.","journal-title":"Nutrients"},{"issue":"27","key":"1738_CR42","doi-asserted-by":"publisher","first-page":"27849","DOI":"10.1074\/jbc.M404087200","volume":"279","author":"M Guzm\u00e1n","year":"2004","unstructured":"Guzm\u00e1n M, Verme JL, Fu J, Oveisi F, Bl\u00e1zquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor \u03b1 (PPAR-\u03b1). J Biol Chem. 2004;279(27):27849\u201354.","journal-title":"J Biol Chem"},{"issue":"4","key":"1738_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/1440-1681.13238","volume":"47","author":"H Tutunchi","year":"2020","unstructured":"Tutunchi H, Saghafi-Asl M, Ostadrahimi A. A systematic review of the effects of oleoylethanolamide, a high\u2010affinity endogenous ligand of PPAR\u2010\u03b1, on the management and prevention of obesity. Clin Exp Pharmacol Physiol. 2020;47(4):543\u201352.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6953","key":"1738_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature01921","volume":"425","author":"J Fu","year":"2003","unstructured":"Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodr\u00edguez de Fonseca F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-\u03b1. Nature. 2003;425(6953):90\u20133.","journal-title":"Nature"},{"issue":"1","key":"1738_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12986-023-00758-9","volume":"20","author":"HD Putera","year":"2023","unstructured":"Putera HD, Doewes RI, Shalaby MN, Ram\u00edrez-Coronel AA, Clayton ZS, Abdelbasset WK, et al. The effect of conjugated linoleic acids on inflammation, oxidative stress, body composition and physical performance: a comprehensive review of putative molecular mechanisms. Nutr Metabolism. 2023;20(1):35\u201350.","journal-title":"Nutr Metabolism"},{"issue":"6860","key":"1738_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/35102582","volume":"414","author":"F Rodriguez de Fonseca","year":"2001","unstructured":"Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860):209\u201312.","journal-title":"Nature"},{"issue":"1","key":"1738_CR47","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1152\/ajpregu.00270.2006","volume":"292","author":"Y Yang","year":"2007","unstructured":"Yang Y, Chen M, Georgeson KE, Harmon CM. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. Am J Physiology-Regulatory Integr Comp Physiol. 2007;292(1):R235-41.","journal-title":"Am J Physiology-Regulatory Integr Comp Physiol"},{"key":"1738_CR48","doi-asserted-by":"crossref","unstructured":"Diniz TA, de Lima Junior EA, Teixeira AA, Biondo LA, da Rocha LAF, Valad\u00e3o IC, et al. Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-\u03b1 signaling in obese mice. Life Sci. 2021;266:1\u20139.","DOI":"10.1016\/j.lfs.2020.118868"},{"issue":"5","key":"1738_CR49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.bjp.0707424","volume":"152","author":"I Matias","year":"2007","unstructured":"Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and \u03b2-cells. Br J Pharmacol. 2007;152(5):676\u201390.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1738_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020394","volume":"13","author":"A Romano","year":"2021","unstructured":"Romano A, Friuli M, Del Coco L, Longo S, Vergara D, Del Boccio P, et al. Chronic oleoylethanolamide treatment decreases hepatic triacylglycerol level in rat liver by a PPAR\u03b3\/SREBP-mediated suppression of fatty acid and triacylglycerol synthesis. Nutrients. 2021;13(2):394\u2013411.","journal-title":"Nutrients"},{"issue":"7","key":"1738_CR51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/sj.npp.1300166","volume":"28","author":"S Gaetani","year":"2003","unstructured":"Gaetani S, Oveisi F, Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology. 2003;28(7):1311\u20136.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1738_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.phrs.2003.12.006","volume":"49","author":"F Oveisi","year":"2004","unstructured":"Oveisi F, Gaetani S, Eng KT-P, Piomelli D. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res. 2004;49(5):461\u20136.","journal-title":"Pharmacol Res"},{"key":"1738_CR53","doi-asserted-by":"crossref","unstructured":"Li B, Tang X, Le G. Dietary habits and Metabolic Health. MDPI; 2023. p. 3975.","DOI":"10.3390\/nu15183975"},{"key":"1738_CR54","doi-asserted-by":"crossref","unstructured":"Slimani N, Freisling H, Illner AK, Huybrechts I. Methods to determine dietary intake. Nutr Res Methodologies. 2015:48\u201370.","DOI":"10.1002\/9781119180425.ch4"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01738-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01738-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01738-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:04:21Z","timestamp":1728371061000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01738-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01738-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Helsinki\u2019s Declaration, the protocol of the study was approved by the ethics committee of Tabriz University of Medical Sciences. An informed written consent form was obtained from all participants. The protocol of the study was approved by the ethics committee of Tabriz University of Medical Sciences with the registration number IR.TBMED.REC.1395.618 in date 03\/10\/2016.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}